Adilia Hormigo, MD, PhD Email Adilia Hormigo
- ASSOCIATE PROFESSOR | Neurology
- ASSOCIATE PROFESSOR | Neurosurgery
- ASSOCIATE PROFESSOR | Medicine
- Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai St. Luke's and Mount Sinai West
- The Mount Sinai Hospital
- New Office 212-824-8579212-824-8579
Adilia Hormigo, MD, PhD is Director of the Neuro-Oncology Program for The Mount SinaiHospital and the Mount Sinai Health System, and Associate Professor in the Department of Neurology, Medicine (Division of Hematology-Oncology) and Neurosurgery. She is a neuro-oncologist specializing in the care of patients with primary brain tumors, CNS metastases, and the neurological complications of cancer and its treatment. She employs a multidisciplinary team approach to ensure that patients receive compassionate, comprehensive care.
Dr. Hormigo obtained her MD with honors from the University of Lisbon Medical School in Portugal, and her PhD from New York University. She completed residencies in Neurology at the University Hospital of Lisbon Medical School, Portuguese Oncological Institute and New York Presbyterian-Weill Medical College of Cornell University and Memorial Sloan-Kettering Cancer Center. She completed both research and clinical neuro-oncology fellowships under Jerome B. Posner. She served as faculty at Memorial Sloan-Kettering Cancer Center and Cornell University. She trained a number of fellows, many of whom are faculty in leading programs of neuro-oncology in the country and abroad.
Her clinical and translational research focuses on new strategies including personalized treatment for patients with brain tumors with emphasis on immunotherapy, developing new biomarkers and studying the microenvironment of brain tumors. Her goal is to achieve the highest level of patient care and clinical excellence. She sees patients at the Ruttenberg Treatment Center of the Tisch Cancer Institute.
- Brain Metastasis
- Brain Tumors
- Lumbar Puncture
- Paraneoplastic Syndromes, Central Nervous System
- Primary Central Nervous System Lymphoma
- Spinal Cord Tumors
Anti-Tumor Therapy, Brain, Cancer, Tumorigenesis
Research Fellow, Memorial Sloan-Kettering Cancer Center
PhD, New York University
MD, PhD, Faculdade De Medicina DA Universidade De Lisboa
Universidade De Lisboa
Universidade De Lisboa
Internship, Internal Medicine
New York Presbyterian - Weill Cornell Medical Center
New York Presbyterian - Weill Cornell Medical Center
Memorial Sloan-Kettering Cancer Center
American Neurological Association
Advanced Techniques in Molecular Neuroscience
Cold Spring Harbor Laboratory
Excellence in Teaching Award for the Neurology Clerkship
Weill Medical College of Cornell University
American Academy of Neurology
Second UCB Neurology Award
Portuguese Society of Neurology
Portuguese Society of Neurology
N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme
The purpose of this research is to study any good and bad effects of combining bevacizumab with another chemotherapy drug called TRC105, and comparing the combination to the usual approach which is chemotherapy with bevacizumab alone. TRC 105 is not approved by the FDA for ...
Iwamoto FM, Hormigo A. Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma. Frontiers in oncology 2014; 4.
Nael K, Bauer AH, Hormigo A, Lemole M, Germano IM, Puig J, Stea B. Multiparametric MRI for Differentiation of Radiation Necrosis From Recurrent Tumor in Patients With Treated Glioblastoma. AJR. American journal of roentgenology 2018 Jan; 210(1).
Connelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. BMC cancer 2016 11; 16(1).
Rhome R, Fisher R, Hormigo A, Parikh RR. Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma. Journal of neuro-oncology 2016 06; 128(2).
Fisher R, Hormigo A. Adjuvant therapy for patients with newly diagnosed glioblastoma. In: Glioblastoma Multiforme: Neurological Symptoms, Therapeutic Management, and Outcome. Hauppauge, NY, Nova Science Publishers;.
Majd N, Wei X, Demopoulos A, Hormigo A, Chari A. Characterization of central nervous system multiple myeloma in the era of novel therapies. Leukemia & lymphoma 2016 07; 57(7).
Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Oct; 20(19).
Ding BS, James D, Iyer R, Falciatori I, Hambardzumyan D, Wang S, Butler JM, Rabbany SY, Hormigo A. Prominin 1/CD133 endothelium sustains growth of proneural glioma. PloS one 2013; 8(4).
Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-oncology 2013 Feb; 15(2).
Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro-oncology 2011 Nov; 13(11).
Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Deangelis LM, Holland EC, Hormigo A. Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. Journal of neuro-oncology 2011 Dec; 105(3).
Hottinger AF, Iwamoto FM, Karimi S, Riedel E, Dantis J, Park J, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Holland EC, DeAngelis LM, Hormigo A. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Annals of neurology 2011 Jul; 70(1).
Pentsova E, Liu A, Rosenblum M, O'Reilly E, Chen X, Hormigo A. Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. Journal of neuro-oncology 2012 Jan; 106(1).
Hormigo A, Ding BS, Rafii S. A target for antiangiogenic therapy: vascular endothelium derived from glioblastoma. Proceedings of the National Academy of Sciences of the United States of America 2011 Mar; 108(11).
Iwamoto FM, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M, Hormigo A. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. Journal of neuro-oncology 2008 Jul; 88(3).
Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. Journal of neuro-oncology 2007 Nov; 85(2).
Hormigo A, Gutin PH, Rafii S. Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. Cancer cell 2007 Jan; 11(1).
Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Oct; 12(19).
Deangelis LM, Hormigo A. Treatment of primary central nervous system lymphoma. Seminars in oncology 2004 Oct; 31(5).
Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. British journal of haematology 2004 Jul; 126(2).
Hormigo A, Liberato B, Lis E, DeAngelis LM. Nonconvulsive status epilepticus in patients with cancer: imaging abnormalities. Archives of neurology 2004 Mar; 61(3).
Hormigo A, DeAngelis LM. Primary ocular lymphoma: clinical features, diagnosis, and treatment. Clinical lymphoma 2003 Jun; 4(1).
Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Aug; 27(23).
Xu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms L, Peck KK, Gutin P, Iorgulescu JB, Kaley T, DeAngelis L, Pentsova E, Nolan C, Grommes C, Chan T, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy P, Supko JG, Tabar V, Omuro A. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Oct; 22(19).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Hormigo did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.